- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Phase I trial tests 'VEGF Trap' dose
Tarrytown, NY—Regeneron Pharmaceuticals Inc. will begin a phase I trial to evaluate the safety and tolerability of its "VEGF Trap" on patients with the wet form of age-related macular deneration.
Tarrytown, NY-Regeneron Pharmaceuticals Inc. will begin a phase I trial to evaluate the safety and tolerability of its "VEGF Trap" on patients with the wet form of age-related macular deneration.
The drug is designed to block vascular endothelial growth factor (VEGF) associated with the abnormal growth of new blood vessels in the eye.
In the dose-escalating study, the drug is administered through a single intravitreal injection, after which patients are evaluated for 3 months to determine its effectiveness and provide dosing guidance for future trials.
